Qiagen (NYSE:QGEN) Shares Sold by Quantbot Technologies LP

Quantbot Technologies LP trimmed its stake in shares of Qiagen (NYSE:QGEN) by 1.1% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 43,608 shares of the company’s stock after selling 504 shares during the period. Quantbot Technologies LP’s holdings in Qiagen were worth $1,875,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Massachusetts Financial Services Co. MA boosted its stake in shares of Qiagen by 8.1% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 24,066,569 shares of the company’s stock worth $1,045,211,000 after acquiring an additional 1,809,486 shares in the last quarter. Vanguard Group Inc. grew its holdings in Qiagen by 1.0% in the fourth quarter. Vanguard Group Inc. now owns 8,815,467 shares of the company’s stock valued at $382,856,000 after purchasing an additional 83,371 shares during the period. Wellington Management Group LLP increased its position in shares of Qiagen by 20.1% in the fourth quarter. Wellington Management Group LLP now owns 7,271,828 shares of the company’s stock valued at $316,463,000 after buying an additional 1,217,712 shares in the last quarter. Norges Bank acquired a new position in shares of Qiagen during the 4th quarter worth approximately $264,322,000. Finally, FIL Ltd lifted its position in shares of Qiagen by 8.5% during the 4th quarter. FIL Ltd now owns 5,099,140 shares of the company’s stock valued at $221,784,000 after buying an additional 399,965 shares in the last quarter. 70.00% of the stock is currently owned by hedge funds and other institutional investors.

Qiagen Price Performance

NYSE QGEN traded up $1.07 during trading hours on Friday, hitting $42.18. 890,327 shares of the company’s stock traded hands, compared to its average volume of 1,149,200. The company has a market capitalization of $9.63 billion, a PE ratio of 28.28, a PEG ratio of 3.17 and a beta of 0.40. The company has a debt-to-equity ratio of 0.25, a current ratio of 1.84 and a quick ratio of 1.45. Qiagen has a 52-week low of $34.74 and a 52-week high of $47.70. The firm’s 50-day moving average is $42.97 and its 200-day moving average is $43.34.

Qiagen (NYSE:QGEN) last posted its quarterly earnings results on Monday, April 29th. The company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.02. Qiagen had a return on equity of 12.59% and a net margin of 17.38%. The business had revenue of $459.00 million during the quarter, compared to analyst estimates of $453.91 million. During the same period in the prior year, the business earned $0.53 earnings per share. The business’s revenue was down 5.4% compared to the same quarter last year. Equities analysts forecast that Qiagen will post 2.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on the stock. Stifel Nicolaus reduced their price objective on shares of Qiagen from $55.00 to $45.00 and set a “hold” rating for the company in a research report on Wednesday, May 1st. Wolfe Research upgraded shares of Qiagen from a “peer perform” rating to an “outperform” rating and set a $50.00 price target for the company in a research report on Thursday, June 27th. Finally, JPMorgan Chase & Co. lifted their price objective on Qiagen from $52.00 to $54.00 and gave the stock an “overweight” rating in a report on Tuesday, June 18th. Three investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $51.05.

Qiagen Company Profile

QIAGEN N.V. offers sample to insight solutions that transform biological materials into molecular insights worldwide. The company provides primary sample technology consumables, such as nucleic stabilization and purification kits for primary sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids from secondary sample materials; and instruments for nucleic acid purification and accessories.